ArticleFrontiers in molecular biosciences2026
Modulation of oxidative stress and metabolic burden in papillary thyroid cancer by SGLT2 and broad DPP inhibition.
Article in Frontiers in molecular biosciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Papillary thyroid cancer (PTC) exhibits metabolic reprogramming consistent with the Warburg effect, characterized by enhanced glycolysis, redox imbalance and dependence on anti-apoptotic mechanisms such as XIAP stabilization. Modulating glucose handling and oxidative status with SGLT2 or broad DPP inhibition may therefore reveal vulnerabilities within this metabolic-apoptotic axis. This study assessed their effects on oxidative stress, glucose-dependent metabolic activity and XIAP distribution and apoptosis-related signaling in thyroid-derived cell models. Methods: Two PTC lines (SCC147, MDA-T32) and a normal thyroid line (NTHY-ORI) were exposed for 48 h to an SGLT2 inhibitor (10 Results: Metabolic profiling showed that SGLT2 inhibition markedly increased IG and MS in SCC147 and NTHY-ORI, consistent with altered glucose-dependent metabolic responses. In contrast, in MDA-T32 SGLT2 inhibition lowered IG/MS values, indicating reduced metabolic activity and a distinct metabolic phenotype. Both inhibitors modulated oxidative stress in a cell-line-dependent manner. SGLT2 inhibition reduced ROS levels in SCC147 (p < 0.01), whereas broad DPP inhibition reduced ROS in NTHY-ORI (p < 0.05), with no significant change observed following SGLT2 inhibition in this cell line. A significant decrease in MDA following iSGLT2 treatment was observed in SCC147 cells, whereas iDPP significantly reduced MDA levels in NTHY-ORI cells. No significant changes were detected in MDA-T32 cells. TAC responses were cell-line dependent. iDPP increased TAC in MDA-T32 and SCC147 cells, whereas both vandetanib and iDPP reduced TAC in NTHY-ORI cells. iSGLT2 did not significantly affect TAC. Extracellular XIAP changes were heterogeneous across cell lines, with the highest levels observed under different conditions depending on the cellular model. Discussion: SGLT2 (10
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.